Phase III
The results of the two long-term trials showed that patients receiving the company’s checkpoint inhibitor, Opdivo (nivolumab), had a long-term overall survival improvement compared to docetaxel chemotherapy alone.
Shares of AVEO Oncology are climbing fast in premarket trading after the company released data that showed positive overall survival benefits of tivozanib in patients with highly refractory metastatic renal cell carcinoma who have received prior immunotherapy treatments.
The fifth annual CAR-TCR Summit will kick off in Boston Tuesday with a focus on advancements in immunotherapies targeting various cancers, as well as challenges that face the field.
Shares of ACADIA Pharmaceuticals are up nearly 70% after the company announced it halted a Phase III psychosis trial early after its Parkinson’s disease drug Nuplazid hit primary endpoints and positioned the company to seek another potential regulatory approval.
The data monitoring committee recommended the trial continue as planned, with an estimated primary completion date in February 2022.
uniQure N.V. announced that the planned enrollment of 56 patients has been achieved in the HOPE-B pivotal trial of etranacogene dezaparvovec, an investigational AAV5-based gene therapy incorporating the patent-protected FIX-Padua variant for the treatment of patients with severe and moderately severe hemophilia B.
Ardelyx said doses of tenapanor, which inhibits controls serum phosphorus by inhibiting the sodium hydrogen exchanger 3 (NHE3), demonstrated a statistically significant reduction in serum phosphorus levels for dialysis patients whose hyperphosphatemia was not previously controlled with phosphate binders alone.
The trials were the PROVE-HF and EVALUATE-HF trials.
AstraZeneca had a big weekend, with positive results from two separate clinical trial programs causing stock to jump 3.4%.
Genentech said Phase III data from the BLOCKSTONE study showed that an individual treated with Xofluza after being exposed to the flu by an infected household member, reduced the risk of developing the flu by 86% compared to placebo.
PRESS RELEASES